Research News

Parkinson's Research

New Dyskinesia Drug Moving Forward in Clinical Testing

Sunday, 26 February 2017

A promising new therapeutic for Parkinson’s disease has secured funding for Phase II testing. The Michael J. Fox Foundation (MJFF) supported early research of this drug, paving the way for its advancement into clinical trials. Parkinson’s disease (PD) is typically…

Bllod test may confirm parkinsons diagnosis

Blood Test May Help Confirm Parkinson’s Diagnosis

Monday, 20 February 2017

Parkinson’s disease (PD) is a complex and varied disorder with many different potential motor and non-motor symptoms. Early on, it can sometimes be difficult to determine whether symptoms are caused by Parkinson’s or an atypical parkinsonism, a condition that shares…

Bllod test may confirm parkinsons diagnosis

Alpha-synuclein Antibody moves a step closer

Monday, 14 November 2016

Therapeutic projects against top target protein alpha-synuclein continue to march through clinical testing and closer to patient hands. Yesterday biotechnology company Prothena announced results from its Phase Ib trial of PRX002, an antibody under investigation as a treatment to slow…

Cognitive Impairment

Cognitive Changes in Parkinson’s Disease

Monday, 17 October 2016

Cognitive impairment, disturbance of memory, thinking and/or language abilities, is a non-motor symptom that can be associated with Parkinson’s. Cognitive disturbances can arise at any time in the course of Parkinson’s disease (PD) and vary widely in severity. Some people…

Neurons

Common Link across Different Causes of Parkinson’s?

Friday, 7 October 2016

Parkinson’s is a variable disease — different in age of onset, experience of symptoms and cause — but a new study points to a potential common link. “Finding a common mechanism behind different suspected causes of Parkinson’s suggests that there…

Vaccine for Parkinson’s Reports Positive Results from Boost Study

Monday, 12 September 2016

New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson’s protein alpha-synuclein. Today the company announced its “boost” follow-up study — funded with a $1.04 million grant from The Michael J. Fox Foundation…

Another Leap Forward for LRRK2 Development

Monday, 29 August 2016

Denali Therapeutics — a San Francisco biotech that launched last year focused on neurodegenerative diseases including Parkinson’s — recently announced it has licensed LRRK2 inhibitor compounds from Genentech. These drug candidates may address the dysfunction seen with LRRK2 mutations, the greatest…